Terms: = Breast cancer AND FGFR2, BFR-1, 2263, ENSG00000066468, TK14, BEK, CD332, JWS, TK25, ECT1, CEK3, K-SAM, CFD1, KGFR
379 results:
1. Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced breast cancer Receiving Palbociclib: Results From the TREnd Trial.
Migliaccio I; Romagnoli D; Galardi F; De Luca F; Biagioni C; Curigliano G; Criscitiello C; Minisini AM; Moretti E; Risi E; Guarducci C; Nardone A; Biganzoli L; Benelli M; Malorni L
JCO Precis Oncol; 2024 Feb; 8():e2300285. PubMed ID: 38427931
[TBL] [Abstract] [Full Text] [Related]
2. Molecular Characterization and Subtyping of breast cancer Cell Lines Provide Novel Insights into cancer Relevant Genes.
Pommerenke C; Nagel S; Haake J; Koelz AL; Christgen M; Steenpass L; Eberth S
Cells; 2024 Feb; 13(4):. PubMed ID: 38391914
[TBL] [Abstract] [Full Text] [Related]
3. Sunitinib in Patients With breast cancer With
Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
[TBL] [Abstract] [Full Text] [Related]
4. First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
Piha-Paul SA; Xu B; Dumbrava EE; Fu S; Karp DD; Meric-Bernstam F; Hong DS; Rodon JA; Tsimberidou AM; Raghav K; Ajani JA; Conley AP; Mott F; Fan Y; Fan J; Peng P; Wang H; Ni S; Sun C; Qiang X; Levin WJ; Ngo B; Ru QC; Wu F; Javle MM
Oncologist; 2024 Apr; 29(4):e514-e525. PubMed ID: 38297981
[TBL] [Abstract] [Full Text] [Related]
5. Cost in the United States of FDA-approved small molecule protein kinase inhibitors used in the treatment of neoplastic and non-neoplastic diseases.
Roskoski R
Pharmacol Res; 2024 Jan; 199():107036. PubMed ID: 38096958
[TBL] [Abstract] [Full Text] [Related]
6. B3GALT6 promotes dormant breast cancer cell survival and recurrence by enabling heparan sulfate-mediated FGF signaling.
Sreekumar A; Lu M; Choudhury B; Pan TC; Pant DK; Lawrence-Paul MR; Sterner CJ; Belka GK; Toriumi T; Benz BA; Escobar-Aguirre M; Marino FE; Esko JD; Chodosh LA
Cancer Cell; 2024 Jan; 42(1):52-69.e7. PubMed ID: 38065100
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer.
Saridogan T; Akcakanat A; Zhao M; Evans KW; Yuca E; Scott S; Kirby BP; Zheng X; Ha MJ; Chen H; Ng PKS; DiPeri TP; Mills GB; Rodon Ahnert J; Damodaran S; Meric-Bernstam F
Sci Rep; 2023 Nov; 13(1):20223. PubMed ID: 37980453
[TBL] [Abstract] [Full Text] [Related]
8. FGF2 drives osteosarcoma metastasis through activating FGFR1-4 receptor pathway-mediated ICAM-1 expression.
Huang YC; Chen WC; Yu CL; Chang TK; I-Chin Wei A; Chang TM; Liu JF; Wang SW
Biochem Pharmacol; 2023 Dec; 218():115853. PubMed ID: 37832794
[TBL] [Abstract] [Full Text] [Related]
9. fgfr2 genetic variants in women with breast cancer.
Dix-Peek T; Dickens C; Augustine TN; Phakathi BP; Van Den Berg EJ; Joffe M; Ayeni OA; Cubasch H; Nietz S; Mathew CG; Hayat M; Neugut AI; Jacobson JS; Ruff P; Duarte RAB
Mol Med Rep; 2023 Dec; 28(6):. PubMed ID: 37830168
[TBL] [Abstract] [Full Text] [Related]
10. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
Broeker CD; Ortiz MMO; Murillo MS; Andrechek ER
Breast Cancer Res; 2023 Oct; 25(1):120. PubMed ID: 37805590
[TBL] [Abstract] [Full Text] [Related]
11. Assessing Mode of Recurrence in breast cancer to Identify an Optimised Follow-Up Pathway: 10-Year Institutional Review.
Horan J; Reid C; Boland MR; Daly GR; Keelan S; Lloyd AJ; Downey E; Walmsley A; Staunton M; Power C; Butt A; Duke D; Hill ADK
Ann Surg Oncol; 2023 Oct; 30(10):6117-6124. PubMed ID: 37479843
[TBL] [Abstract] [Full Text] [Related]
12. Futibatinib, an Irreversible FGFR1-4 Inhibitor for the Treatment of FGFR-Aberrant Tumors.
Javle M; King G; Spencer K; Borad MJ
Oncologist; 2023 Nov; 28(11):928-943. PubMed ID: 37390492
[TBL] [Abstract] [Full Text] [Related]
13. fgfr2 Controls Growth, Adhesion and Migration of Nontumorigenic Human Mammary Epithelial Cells by Regulation of Integrin β1 Degradation.
Mieczkowski K; Popeda M; Lesniak D; Sadej R; Kitowska K
J Mammary Gland Biol Neoplasia; 2023 May; 28(1):9. PubMed ID: 37191822
[TBL] [Abstract] [Full Text] [Related]
14. Evaluation of the Association between
Jahan N; Begum M; Barek MA; Aziz MA; Hossen MS; Bhowmik KK; Akter T; Islam MR; Abdulabbas HS; Islam MS
Genes (Basel); 2023 Mar; 14(4):. PubMed ID: 37107577
[TBL] [Abstract] [Full Text] [Related]
15. The sequence kernel association test for multicategorical outcomes.
Jiang Z; Zhang H; Ahearn TU; Garcia-Closas M; Chatterjee N; Zhu H; Zhan X; Zhao N
Genet Epidemiol; 2023 Sep; 47(6):432-449. PubMed ID: 37078108
[TBL] [Abstract] [Full Text] [Related]
16. Decoding the Conformational Selective Mechanism of FGFR Isoforms: A Comparative Molecular Dynamics Simulation.
Zhang M; Yasen M; Lu S; Ma DN; Chai Z
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985681
[TBL] [Abstract] [Full Text] [Related]
17. Derazantinib, a fibroblast growth factor receptor inhibitor, inhibits colony-stimulating factor receptor-1 in macrophages and tumor cells and in combination with a murine programmed cell death ligand-1-antibody activates the immune environment of murine syngeneic tumor models.
El Shemerly M; Zanini E; Lecoultre M; Walker PR; Kellenberger L; Lane HA; McSheehy PMJ
Anticancer Drugs; 2023 Oct; 34(9):1035-1045. PubMed ID: 36729099
[TBL] [Abstract] [Full Text] [Related]
18. Defining genomic, transcriptomic, proteomic, epigenetic, and phenotypic biomarkers with prognostic capability in male breast cancer: a systematic review.
Chatterji S; Krzoska E; Thoroughgood CW; Saganty J; Liu P; Elsberger B; Abu-Eid R; Speirs V
Lancet Oncol; 2023 Feb; 24(2):e74-e85. PubMed ID: 36725152
[TBL] [Abstract] [Full Text] [Related]
19. Aggregation tests identify new gene associations with breast cancer in populations with diverse ancestry.
Mueller SH; Lai AG; Valkovskaya M; Michailidou K; Bolla MK; Wang Q; Dennis J; Lush M; Abu-Ful Z; Ahearn TU; Andrulis IL; Anton-Culver H; Antonenkova NN; Arndt V; Aronson KJ; Augustinsson A; Baert T; Freeman LEB; Beckmann MW; Behrens S; Benitez J; Bermisheva M; Blomqvist C; Bogdanova NV; Bojesen SE; Bonanni B; Brenner H; Brucker SY; Buys SS; Castelao JE; Chan TL; Chang-Claude J; Chanock SJ; Choi JY; Chung WK; ; Colonna SV; ; Cornelissen S; Couch FJ; Czene K; Daly MB; Devilee P; Dörk T; Dossus L; Dwek M; Eccles DM; Ekici AB; Eliassen AH; Engel C; Evans DG; Fasching PA; Fletcher O; Flyger H; Gago-Dominguez M; Gao YT; García-Closas M; García-Sáenz JA; Genkinger J; Gentry-Maharaj A; Grassmann F; Guénel P; Gündert M; Haeberle L; Hahnen E; Haiman CA; Håkansson N; Hall P; Harkness EF; Harrington PA; Hartikainen JM; Hartman M; Hein A; Ho WK; Hooning MJ; Hoppe R; Hopper JL; Houlston RS; Howell A; Hunter DJ; Huo D; ; Ito H; Iwasaki M; Jakubowska A; Janni W; John EM; Jones ME; Jung A; Kaaks R; Kang D; Khusnutdinova EK; Kim SW; Kitahara CM; Koutros S; Kraft P; Kristensen VN; Kubelka-Sabit K; Kurian AW; Kwong A; Lacey JV; Lambrechts D; Le Marchand L; Li J; Linet M; Lo WY; Long J; Lophatananon A; Mannermaa A; Manoochehri M; Margolin S; Matsuo K; Mavroudis D; Menon U; Muir K; Murphy RA; Nevanlinna H; Newman WG; Niederacher D; O'Brien KM; Obi N; Offit K; Olopade OI; Olshan AF; Olsson H; Park SK; Patel AV; Patel A; Perou CM; Peto J; Pharoah PDP; Plaseska-Karanfilska D; Presneau N; Rack B; Radice P; Ramachandran D; Rashid MU; Rennert G; Romero A; Ruddy KJ; Ruebner M; Saloustros E; Sandler DP; Sawyer EJ; Schmidt MK; Schmutzler RK; Schneider MO; Scott C; Shah M; Sharma P; Shen CY; Shu XO; Simard J; Surowy H; Tamimi RM; Tapper WJ; Taylor JA; Teo SH; Teras LR; Toland AE; Tollenaar RAEM; Torres D; Torres-Mejía G; Troester MA; Truong T; Vachon CM; Vijai J; Weinberg CR; Wendt C; Winqvist R; Wolk A; Wu AH; Yamaji T; Yang XR; Yu JC; Zheng W; Ziogas A; Ziv E; Dunning AM; Easton DF; Hemingway H; Hamann U; Kuchenbaecker KB
Genome Med; 2023 Jan; 15(1):7. PubMed ID: 36703164
[TBL] [Abstract] [Full Text] [Related]
20. Risk stratification in subpectoral to prepectoral pocket conversion to reduce post-reconstruction animation deformity.
Cerceo JR; Cai L; Yesantharao P; Thornton B; Nazerali R
J Plast Reconstr Aesthet Surg; 2023 Feb; 77():253-261. PubMed ID: 36592536
[TBL] [Abstract] [Full Text] [Related]
[Next]
